The Paradox of the Prescription Charge: Co-payments in British Pharmaceuticals
Prescriptions account for around 10% of UK National Health Service (NHS) expenditures. In an effort to control costs and to recoup expenditures government imposed prescription charges in 1951. Before their temporary abolition in 1965, charge income covered about 20% of costs. But both the charge and the proportion of the population exempted from paying it have increased substantially over the years. Consequently, although the charge has increased from 9% to 53% of the cost of the average script since 1978, total income from the charge has remained less than ten percent of total NHS prescription costs and consumption in the presence of other less easily controled factors such as an ageing population and unemployment. A patient co-payment such as the charge appears to be a significant determinant of health demand.
To our knowledge, this item is not available for
download. To find whether it is available, there are three
1. Check below under "Related research" whether another version of this item is available online.
2. Check on the provider's web page whether it is in fact available.
3. Perform a search for a similarly titled item that would be available.
|Date of creation:||Oct 1995|
|Date of revision:|
|Contact details of provider:|| Postal: School of Economics and Finance, University of St. Andrews, Fife KY16 9AL|
Phone: 01334 462420
Fax: 01334 462438
Web page: http://crieff.wordpress.com/
More information through EDIRC
When requesting a correction, please mention this item's handle: RePEc:san:crieff:9504. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (the School of Economics)
If references are entirely missing, you can add them using this form.